Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CX2101A in Healthy Chinese Adults
NCT06860282Phase 1Completed
- Sponsor
- HeraNova Lifesciences
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cx2101a in coronavirus disease 2019 (COVID-19) (9 arms), sponsored by HeraNova Lifesciences. Primary endpoints: Rate and severity of treatment-emergent adverse events, Vital signs and 2 more. Started Dec 2022; status: completed.
02
Drugs
cx2101a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06860282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860282.